Skip to Content
Søg Menu

Starten på en ny tilgang til behandling af CLL-patienter med relaps

Test af tidsbegrænset og individuelt tilpasset behandling for patienter med den mest alvorlige CLL diagnose, giver håb for mere individuelt tilpassede forløb. Se denne MEDtalk, hvor Carsten Utoft Niemann opsummerer resultaterne fra Vision HO 141 studiet, som han var med til at præsentere på ASH21.
Carsten Utoft Niemann,

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
EHA24CLL
Paolo Ghia

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Paolo Ghia
EHA24CLL Play the Video 02:42
Alessandra Tedeschi

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

/ Alessandra Tedeschi
EHA24CLL Play the Video 01:52

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ BestPractice Nordic
ASH23CLL
Jeff P. Sharman

No Increased Risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Jeff P. Sharman
ASH23CLL Play the Video 1:45
Jeff P. Sharman

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

/ Jeff P. Sharman
ASH23CLL Play the Video 2:45

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

/ BestPractice Nordic
ASH23CLL
Peter Hillmen

New Standard of Care for Previously Untreated CLL

/ Peter Hillmen
ASH23CLL Play the Video 5:40
Back to top